The planned cohorts for the Trans PORTEC RAINBO programme of clinical trials aim to refine the adjuvant treatment of patients with endometrial cancer based on molecular profile including POLEmut status, dMMR, no specific molecular profile (NSMP) and abnormal p53 (p53abn). Here, TP53 is linked to endometrial cancer.